Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navitoclax - AbbVie

Drug Profile

Navitoclax - AbbVie

Alternative Names: ABT-263; RG 7423; RG 7433

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Genentech
  • Class Antineoplastics; Benzamides; Morpholines; Piperazines; Small molecules; Sulfones
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Myelofibrosis
  • Phase I Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Chronic lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 03 Oct 2019 Phase-II clinical trials in Myelofibrosis (Combination therapy, Second-line therapy or greater, Adjunctive treatment) in Japan (PO) (NCT04041050)
  • 03 Oct 2019 Phase-II clinical trials in Myelofibrosis (Second-line therapy or greater, Adjunctive treatment) in Japan (PO) (NCT04041050)
  • 01 Aug 2019 AbbVie plans a phase I trial for Myeloproliferative neoplasm (In adults, In the elderly, Combination therapy, Second-line or greater therapy) in Japan (PO) (NCT04041050)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top